Antitumor aldophosphamide glycoside and dideoxyuridine derivatives
作者： Yugiang Wang , David Farquhar
DOI:
关键词: Clonogenic assay 、 Bone marrow 、 Esterase 、 Tumor cells 、 Chemistry 、 Aldophosphamide 、 Glycoside 、 Acrolein 、 Stereochemistry 、 Elimination reaction
摘要: A compound having the structure: ##STR1## wherein R is CH3, C2 H5, C3 H7, t-C4 H9 or C6 H5 ; R1 NH2, NHCH3, NHC2 NHC3 NHC4 H9, NHCH2 CH2 Cl, NHC6 N(CH3)2, N(C2 H5)2, N(C3 H7)2, NCH3 (C2 H5), (C3 H7), N(CH2 Cl)2, NHOH, NHNHCO2 C(CH3)3, OCH3, OC2 OC3 OC4 OC6 C4 NO2 NH2 and R2 Cl Cl)2. These compounds may be used to eliminate occult leukemic clonogenic cells from bone marrow by contacting with a solution comprising levels of said sufficient cells. Analogously, tumor in host organ eliminated treatment host's this description. Compounds description are stable aldophosphamide analogs activatable action an esterase subsequent E-2 elimination reaction form acrolein phosphoramidic mustard formula: analog spontaneous mustard, formula ##STR2##
lens.org 参考文章(40)
Montgomery Ja, Struck Rf, Synthesis and structure-activity relationships of pre-activated analogs of cyclophosphamide (NSC-26271). Cancer treatment reports. ,vol. 60, pp. 381- 393 ,(1976)
S Tamura, Uridine-5-monophosphate compositions ,(1973)
T Wagner, H J Hohorst, G Peter, Studies on 4-hydroperoxycyclophosphamide (NSC-181815): a simple preparation method and its application for the synthesis of a new class of "activated" sulfur-containing cyclophosphamide (NSC-26271) derivatives. Cancer treatment reports. ,vol. 60, pp. 429- 435 ,(1976)
Federico Arcamone, Sergio Penco, Gian P. Vicario, Daunorubicin and doxorubicin labelled with 14 C at the 14-position and processes for their preparation ,(1978)
SJ Sharkis, GW Santos, M Colvin, Elimination of Acute Myelogenous Leukemic Cells From Marrow and Tumor Suspensions in the Rat With 4-Hydroperoxycyclophosphamide Blood. ,vol. 55, pp. 521- 523 ,(1980) , 10.1182/BLOOD.V55.3.521.521
Nobuhiko Katsunuma, Nucleoside derivatives and an antileukemial agent containing the same as an active ingredient ,(1979)
R. E. Ploemacher, P. G. J. Nikkels, J. P. De Jong, J. S. A. Voerman, K. G. M. Brockbank, Comparative in vitro effects of cyclophosphamide derivatives on murine bone marrow-derived stromal and hemopoietic progenitor cell classes. Cancer Research. ,vol. 45, pp. 4001- 4005 ,(1985)
Hiromichi Itoh, Kiyofumi Fukukawa, Masatoshi Tujino, Satoshi Shuto, Nucleoside-phospholipid conjugate ,(1987)
N. E. Sladek, G. J. Landkamer, Restoration of Sensitivity to Oxazaphosphorines by Inhibitors of Aldehyde Dehydrogenase Activity in Cultured Oxazaphosphorine-resistant L1210 and Cross-Linking Agent-resistant P388 Cell Lines Cancer Research. ,vol. 45, pp. 1549- 1555 ,(1985)
Kenneth B. McCredie, David Farquhar, Borje S. Andersson, Yuqiang Wang, Miloslav Beran, The effects of acetaldophosphamide, a novel stable aldophosphamide analogue, on normal human and leukemic progenitor cells in vitro: implications for use in bone marrow purging. Cancer Research. ,vol. 48, pp. 339- 345 ,(1988)